業績一覧

2021年 業績

Kato H, Takeuchi M, Horita N, Ishido T, Mizuki R, Kawagoe T, Shibuya E, Yuda K, Ishido M, Mizuki Y, Hayashi T, Meguro A, Kirino Y, Minegishi K, Nakano H, Yoshimi R, Kurosawa M, Fukumoto T, Takeno M, Hotta K, Kaneko T, Mizuki N. HLA-A26 is a Risk Factor for Behçet's Disease Ocular Lesions. Mod Rheumatol. ;31(1):214-218. 2021 Jan.

Soejima Y, Kirino Y, Takeno M, Kurosawa M, Takeuchi M, Yoshimo R, Sugiyama Y, Ohno S, Asami Y, Sekiguchi A, Igarashi T, Nagaoka S, Ishigatsubo Y, Makajima H, Mizuki N. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet's disease in Japan. Arthritis Res Ther, 23(1) 49. 2021 Feb.

Nakamura K, Tsunemi Y, Kaneko F, Alpsoy E. Mucocutaneous manifestations of Behçet’s disease. Frontiers in Medicine.; https://doi.org/10.3389/fmed.2020.613432. 01, February, 2021

Hirahara L, Kirino Y, Soejima Y, Takeno M, Takase-Minegishi K. Yoshimo R, Takeuchi M, Mizuki N, Makajima H. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study. Mod Rheumatol. Online ahead of print.

このページのトップへ戻る